Cancer Res. 63:7861) and infectious diseases such as microsporidiosis, leishmaniasis, and malaria (Zhang et al. (2002) J. Biomed. Sci. 9:34). Notably, inhibition of MetAP2 activity in obese and obese-diabetic animals leads to a reduction in body weight in part by increasing the oxidation of fat and in part by reducing the consumption of food (Rupnick et al. (2002) Proc. Natl. Acad. Sci. USA 99:10730).

[0005] Such MetAP2 inhibitors may be useful as well for patients with excess adiposity and conditions related to adiposity including type 2 diabetes, hepatic steatosis, and cardiovascular disease (*via* e.g. ameliorating insulin resistance, reducing hepatic lipid content, and reducing cardiac workload). Accordingly, compounds capable of modulating MetAP2 are needed to address the treatment of obesity and related diseases as well as other ailments favorably responsive to MetAP2 modulator treatment.

SUMMARY

[0006] The ~~invention~~present disclosure provides, for example, compounds which may be modulators of MetAP2, and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions containing them as an active ingredient both alone or in combination with other agents, as well as provides for their use as medicaments and/or in the manufacture of medicaments for the inhibition of MetAP2 activity in warm-blooded animals such as humans. In particular this ~~invention~~present disclosure relates to compounds useful for the treatment of obesity, type 2 diabetes, and other obesity-associated conditions. Also provided are pharmaceutical compositions comprising at least one disclosed compound and a pharmaceutically acceptable carrier.

[0007] In an embodiment, provided herein are compounds represented by formula I and II:



Formula I or



Formula II

or pharmaceutically acceptable salts, stereoisomers, esters or prodrugs thereof, where A, B^1, B^2, D^1, D^2, R^{A1}, R^{A2}, R^{B1}, R^{B2}, Y, X^1, X^2, and n are as defined herein.

[0007a] In an aspect, there is provided a tricyclic compound represented by:



Formula I or



Formula II

wherein:

B^1 is a 3-6 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;

B^2 is a 3-6 membered saturated heterocyclic or carbocyclic ring;

wherein the ring B^1 or B^2 is optionally substituted by one or more fluorine atoms on any of the available carbon atoms;

D^1 is a 5-7 membered heterocyclic, carbocyclic, heteroaromatic or aromatic ring;

D^2 is a 5-7 membered heterocyclic or carbocyclic ring;

wherein B^1 is fused to D^1 such that the two atoms shared by B^1 and D^1 are both carbon and B^2 is fused to D^2 such that the two atoms shared by B^2 and D^2 are both carbon; and wherein for Formula I the bond common to both the B^1 and D^1 rings is a single or double bond;

X^1 is selected from the group consisting of: $^{+}$-$C(R^{D1}R^{D2})$-*, $^{+}$-W^1-*, $^{\cdot}$-$C(R^{D1}R^{D2})$-$C(R^{D5}R^{D6})$-*, $^{+}$-$C(R^{C1})$=$C(R^{C2})$-*, $^{+}$-W^2-$C(R^{D5}R^{D6})$-*, $^{+}$-W^2-C(O)-*, $^{+}$-$C(R^{D1}R^{D2})$-W^4-*, $^{\cdot}$-N=$C(R^{C2})$-*, $^{\cdot}$-$C(R^{C1})$=N-*, $^{+}$-$C(R^{D1}R^{D2})$-$C(R^{D3}R^{D4})$-$C(R^{D5}R^{D6})$-*, $^{+}$-W^2-$C(R^{D3}R^{D4})$-$C(R^{D5}R^{D6})$-*, $^{+}$-W^2-C(O)-$C(R^{D5}R^{D6})$-*, $^{+}$-$C(R^{D1}R^{D2})$-W^3-$C(R^{D5}R^{D6})$-*, $^{+}$-$C(R^{D1}R^{D2})$-W^3-C(O)-*, $^{+}$-$C(R^{D1}R^{D2})$-$C(R^{D3}R^{D4})$-W^4-* and $^{\cdot}$-$C(R^{D1}R^{D2})$-C(O)-W^4-*; wherein the $^{\cdot}$ and * indicate the attachment points of X^1 as indicated in Formula I;

X^2 is selected from the group consisting of: $^{+}$-$C(R^{D1}R^{D2})$-*, $^{+}$-W^1-*, $^{\cdot}$-$C(R^{D1}R^{D2})$-$C(R^{D5}R^{D6})$-*, $^{+}$-W^2-$C(R^{D5}R^{D6})$-*, $^{\cdot}$-W^2-C(O)-*, $^{\cdot}$-$C(R^{D1}R^{D2})$-W^4-*, $^{\cdot}$-$C(R^{D1}R^{D2})$-$C(R^{D3}R^{D4})$-$C(R^{D5}R^{D6})$-*, $^{\cdot}$-W^2-$C(R^{D3}R^{D4})$-$C(R^{D5}R^{D6})$-*, $^{+}$-W^2-C(O)-$C(R^{D5}R^{D6})$-*, $^{+}$-$C(R^{D1}R^{D2})$-W^3-$C(R^{D5}R^{D6})$-*, $^{+}$-$C(R^{D1}R^{D2})$-W^3-C(O)-*, $^{+}$-$C(R^{D1}R^{D2})$-$C(R^{D3}R^{D4})$-W^4-* and $^{\cdot}$-$C(R^{D1}R^{D2})$-C(O)-W^4-*; wherein the $^{\cdot}$ and * indicate the attachment points of X^2 as indicated in Formula II;

Y is selected from the group consisting of: a bond, *-CH_2-$^{\#}$, *-O-$^{\#}$, *-CH_2-CH_2-$^{\#}$, *-O-CH_2-$^{\#}$, *-CH_2-O-$^{\#}$, *-CH_2-CH_2-CH_2-$^{\#}$, *-O-CH_2-CH_2-$^{\#}$ and *-CH_2-O-CH_2-$^{\#}$; wherein the * and $^{\#}$ indicate the attachment points of Y as indicated in Formula I or Formula II;

W^1 is selected from the group consisting of O, S or $N(R^{N1})$;

W^2 is selected from the group consisting of O or $N(R^{N2})$;

W^3 is selected from the group consisting of O or $N(R^{N3})$;

W^4 is selected from the group consisting of O or $N(R^{N4})$;

A is a ring selected from the group consisting of phenyl, a 5-6 membered heteroaryl having 1, 2 or 3 heteroatoms each selected from S, N or O, and a 4–7 membered heterocycle having 1, 2 or 3 heteroatoms each selected from N or O;

R^{B1} and R^{B2} are independently selected from the group consisting of H, F, OH, CN, C_{1-2}alkoxy or C_{1-3}alkyl; wherein C_{1-3}alkyl and C_{1-2}alkoxy are optionally substituted by a group selected from OH, C_{1-2}alkoxy, CN or one or more fluorine atoms;

R^{A1} is selected, independently for each occurrence, from the group consisting of hydrogen, hydroxyl, cyano, halogen, C_{1-4}alkyl or C_{1-3}alkoxy; wherein C_{1-4}alkyl, or C_{1-3}alkoxy may be optionally substituted by oneor more fluorines;

n is 0, 1, or 2;

R^{A2} is selected from the group consisting of hydrogen, R^iR^jN-, heterocyclyl, heterocyclyloxy and heterocyclyl-(NR^a)-; wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R^g and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R^h; or

R^{A2} is selected from the group consisting of: C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{3-6}alkenyloxy, C_{3-6}alkynyloxy, C_{3-6}cycloalkoxy, C_{1-6}alkyl-$S(O)_w$- (wherein w is 0, 1 or 2), C_{1-6}alkyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-carbonyl-, C_{1-6}alkylcarbonyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-carbonyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-SO_2-, C_{1-6}alkyl-SO_2-$N(R^a)$-, C_{1-6}alkoxycarbonyl-$N(R^a)$-, C_{1-6}alkylcarbonyl-$N(R^a)$-C_{1-6}alkyl-, C_{1-6}alkyl-$N(R^a)$-carbonyl-C_{1-6}alkyl-, C_{1-6}alkoxyC_{1-6}alkyl-; wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{3-6}alkenyloxy, C_{3-6}alkynyloxy, C_{3-6}cycloalkoxy, C_{1-6}alkyl-$S(O)_w$-, C_{1-6}alkyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-carbonyl-, C_{1-6}alkylcarbonyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-carbonyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-SO_2-, C_{1-6}alkyl-SO_2-$N(R^a)$-, C_{1-6}alkoxycarbonyl-$N(R^a)$-, C_{1-6}alkylcarbonyl-$N(R^a)C_{1-6}$alkyl-, C_{1-6}alkyl-$N(R^a)$-carbonyl-C_{1-6}alkyl-, C_{1-6}alkoxy-C_{1-6}alkyl may optionally be substituted by R^p, phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR^a)-, heterocyclyl, heterocyclyloxy or heterocyclyl-$N(R^a)$-; and wherein said heteroaryl or phenyl may optionally be substituted with one or more substituents selected from R^f; and wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R^g; and wherein if said

heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R^h;

R^{D1} and R^{D2} are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl and C_{1-2}alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano or hydroxyl;

R^{D3} and R^{D4} are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C_{1-3}alkyl or C_{1-3}alkoxy; wherein the C_{1-3} alkyl and C_{1-3} alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or $N(R^aR^b)$;

R^{D5} and R^{D6} are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl and C_{1-2}alkoxy may optionally be substituted by a substituent or substituents selected from the group consisting of: one or more fluorine atoms.cyano, hydroxyl or $N(R^aR^b)$;

R^{C1} is selected from the group consisting of hydrogen, halogen, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl or C_{1-2}alkoxy may optionally be substituted by one or more fluorine atoms;

R^{C2} is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl and C_{1-2}alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or $N(R^aR^b)$;

R^{N1} is selected from the group consisting of hydrogen or C_{1-2}alkyl;

R^{N2} is selected from the group consisting of hydrogen or C_{1-2}alkyl;

R^{N3} is selected from the group consisting of hydrogen, C_{1-3}alkyl or C_{1-2}alkylcarbonyl; wherein the C_{1-3}alkyl and C_{1-2}alkylcarbonyl may optionally be substituted by a substituent or substituents selected from the group consisting of: one or more fluorines, cyano, hydroxyl or $N(R^aR^b)$;

R^{N4} is selected from the group consisting of hydrogen, C_{1-3}alkyl or C_{1-2}alkylcarbonyl; wherein the C_{1-3}alkyl and C_{1-2}alkylcarbonyl may optionally be substituted by a substituent or substituents selected from the group consisting of: one or more fluorines, cyano, hydroxyl or $N(R^aR^b)$;

R^a and R^b are independently selected, for each occurrence, from the group consisting of hydrogen and C_{1-3}alkyl; wherein C_{1-3}alkyl may optionally be substituted by one or more substituents selected from fluorine, cyano, oxo and hydroxyl;

or R^a and R^b, together with the nitrogen to which they are attached, may form a 4-6 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring may optionally be substituted by one or more substituents selected from the group consisting of fluorine, cyano, oxo or hydroxyl;

R^f is independently selected, for each occurrence, from the group consisting of R^p, hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, (wherein wherein w is 0, 1 or 2), C_{1-6}alkylcarbonyl-$N(R^a)$- and C_{1-6}alkoxycarbonyl-$N(R^a)$-; wherein C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, C_{1-6}alkylcarbonyl-$N(R^a)$-, C_{1-6}alkoxycarbonyl-$N(R^a)$- may be optionally substituted by one or more substituents selected from R^p;

R^g is independently selected for each occurrence from the group consisting of R^p, hydrogen, oxo, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, (wherein w is 0, 1 or 2), C_{1-6}alkylcarbonyl-$N(R^a)$- and C_{1-6}alkoxycarbonyl-$N(R^a)$-; wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, C_{1-6}alkylcarbonyl-$N(R^a)$-, C_{1-6}alkoxycarbonyl-$N(R^a)$- may be optionally substituted by one or more substituents selected from R^p;

R^h is independently selected for each occurrence from the group consisting of hydrogen, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkyl-$S(O)_2$-, C_{1-6}alkoxycarbonyl-, R^iR^jN-carbonyl- and R^iR^jN-SO_2-; wherein C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl and C_{1-6}alkyl-$S(O)_2$-, C_{1-6}alkylcarbonyl- may optionally be substituted by one or more substituents selected from R^p;

R^i and R^j are selected independently for each occurrence from the group consisting of hydrogen, C_{1-4}alkyl C_{3-6}cycloalkyl, heterocyclyl and heterocyclylcarbonyl; wherein C_{1-4}alkyl and C_{3-6}cycloalkyl may be optionally substituted by one or more substituents selected from fluorine, hydroxyl, cyano, R^aR^bN-, R^aR^bN-carbonyl- and C_{1-3}alkoxy and wherein heterocyclyl and heterocyclylcarbonyl may be optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, halo-C_{1-6}-alkyl, hydroxyl-C_{1-6}-alkyl, R^aR^bN-C_{1-6}alkyl- and C_{1-6}-alkoxy-C_{1-6}-alkyl group; and wherein if said heterocyclyl or heterocyclylcarbonyl contains a –NH moiety that nitrogen may optionally be substituted by

one or more groups C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkyl-$S(O)_2$- and C_{1-6}-alkylcarbonyl; or R^i and R^j taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-7 membered heterocyclic ring may be optionally substituted on carbon by one or more substituents selected from the group consisting of fluorine, hydroxyl, oxo, cyano, C_{1-6}alkyl, C_{1-6}alkoxy, R^aR^bN-, R^aR^bN-SO_2- and R^aR^bN-carbonyl-; wherein said C_{1-6}alkyl or C_{1-6}alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and wherein the 4-7 membered heterocyclic ring may be optionally substituted on nitrogen by one or more substituents selected from the group consisting of C_{1-6}alkyl and R^aR^bN-carbonyl-; and wherein said C_{1-6}alkyl may be optionally substituted by one or more substituents selected from the group consisting of fluorine, hydroxyl, cyano;

R^p is independently selected, for each occurrence, from the group consisting of halogen, hydroxyl, cyano, C_{1-6}alkoxy, R^iR^jN-, R^iR^jN-carbonyl-, R^iR^jN-SO_2- and R^iR^jN-carbonyl-$N(R^a)$-;

and pharmaceutically acceptable salts, stereoisomers, esters and prodrugs thereof.

[0007b] In another aspect, there is provided a tricyclic compound represented by:



Formula III;

wherein:

B^1 is a 3-6 membered saturated or partially unsaturated heterocyclic or carbocyclic ring; wherein the ring B^1 is optionally substituted by one or more fluorine atoms on any of the available carbon atoms;

D^1 is a 5-7 membered heterocyclic, carbocyclic, heteroaromatic or aromatic ring; wherein B^1 is fused to D^1 such that the two atoms shared by B^1 and D^1 are both carbon; and wherein the bond common to both the B^1 and D^1 rings is a single or double bond;

X^1 is selected from the group consisting of: $^{+}$-$C(R^{D1}R^{D2})$-*, $^{+}$-W^1-*, $^{+}$-$C(R^{D1}R^{D2})$-$C(R^{D5}R^{D6})$-*, $^{+}$-$C(R^{C1})$=$C(R^{C2})$-*, $^{+}$-W^2-$C(R^{D5}R^{D6})$-*, $^{+}$-W^2-C(O)-*, $^{+}$-$C(R^{D1}R^{D2})$-W^4-*, $^{+}$-N=$C(R^{C2})$-*, $^{+}$-$C(R^{C1})$=N-*, $^{+}$-$C(R^{D1}R^{D2})$-$C(R^{D3}R^{D4})$-$C(R^{D5}R^{D6})$-*, $^{+}$-W^2-$C(R^{D3}R^{D4})$-$C(R^{D5}R^{D6})$-*, $^{+}$-W^2-C(O)-$C(R^{D5}R^{D6})$-*, $^{+}$-$C(R^{D1}R^{D2})$-W^3-$C(R^{D5}R^{D6})$-*, $^{+}$-$C(R^{D1}R^{D2})$-W^3-C(O)-*, $^{+}$-$C(R^{D1}R^{D2})$-$C(R^{D3}R^{D4})$-W^4-* and $^{+}$-$C(R^{D1}R^{D2})$-C(O)-W^4-*; wherein the $^{+}$ and * indicate the attachment points of X^1 as indicated in Formula III;

Y is selected from the group consisting of: a bond, *-CH_2-$^{\#}$, *-O-$^{\#}$, *-CH_2-CH_2-$^{\#}$, *-O-CH_2-$^{\#}$, *-CH_2-O-$^{\#}$, *-CH_2-CH_2-CH_2-$^{\#}$, *-O-CH_2-CH_2-$^{\#}$ and *-CH_2-O-CH_2-$^{\#}$; wherein the * and $^{\#}$ indicate the attachment points of Y as indicated in Formula III;

W^1 is selected from the group consisting of O, S or N(R^{N1});

W^2 is selected from the group consisting of O or N(R^{N2});

W^3 is selected from the group consisting of O or N(R^{N3});

W^4 is selected from the group consisting of O or N(R^{N4});

R^{A1} is selected, independently for each occurrence, from the group consisting of hydrogen, hydroxyl, cyano, halogen, C_{1-4}alkyl or C_{1-3}alkoxy; wherein C_{1-4}alkyl, or C_{1-3}alkoxy may be optionally substituted by one or more fluorines;

n is 1 or 2;

R^{A2} is selected from the group consisting of hydrogen, R^iR^iN-, heterocyclyl, heterocyclyloxy and heterocyclyl-(NR^a)-; wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R^g and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R^h; or

R^{A2} is selected from the group consisting of: C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{3-6}alkenyloxy, C_{3-6}alkynyloxy, C_{3-6}cycloalkoxy, C_{1-6}alkyl-$S(O)_w$- (wherein w is 0, 1 or 2), C_{1-6}alkyl-N(R^a)-, C_{1-6}alkyl-N(R^a)-carbonyl-, C_{1-6}alkylcarbonyl-N(R^a)-, C_{1-6}alkyl-N(R^a)-carbonyl-N(R^a)-, C_{1-6}alkyl-N(R^a)-SO_2-, C_{1-6}alkyl-SO_2-N(R^a)-, C_{1-6}alkoxycarbonyl-N(R^a)-, C_{1-6}alkylcarbonyl-N(R^a)-C_{1-6}alkyl-, C_{1-6}alkyl-N(R^a)-carbonyl-C_{1-6}alkyl-, C_{1-6}alkoxyC_{1-6}alkyl-; wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{3-6}alkenyloxy, C_{3-6}alkynyloxy, C_{3-6}cycloalkoxy, C_{1-6}alkyl-$S(O)_w$-, C_{1-6}alkyl-N(R^a)-, C_{1-6}alkyl-N(R^a)-carbonyl-, C_{1-6}alkylcarbonyl-N(R^a)-, C_{1-6}alkyl-N(R^a)-carbonyl-N(R^a)-, C_{1-6}alkyl-N(R^a)-SO_2-, C_{1-6}alkyl-SO_2-N(R^a)-, C_{1-6}alkoxycarbonyl-N(R^a)-, C_{1-6}alkylcarbonyl-N(R^a)C_{1-6}alkyl-, C_{1-6}alkyl-N(R^a)-carbonyl-C_{1-6}alkyl-, C_{1-6}alkoxy-C_{1-6}alkyl may optionally be substituted by R^P, phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR^a)-, heterocyclyl, heterocyclyloxy or heterocyclyl-N(R^a)-; and wherein said heteroaryl or phenyl may optionally be substituted with one or more substituents selected from R^f; and wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R^g; and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R^h;

R^{D1} and R^{D2} are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl and C_{1-2}alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano or hydroxyl;

R^{D3} and R^{D4} are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C_{1-3}alkyl or C_{1-3}alkoxy; wherein the C_{1-3} alkyl and C_{1-3} alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or $N(R^aR^b)$;

R^{D5} and R^{D6} are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl and C_{1-2}alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or $N(R^aR^b)$;

R^{C1} is selected from the group consisting of hydrogen, halogen, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl or C_{1-2}alkoxy may optionally be substituted by one or more fluorine atoms;

R^{C2} is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl and C_{1-2}alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or $N(R^aR^b)$;

R^{N1} is selected from the group consisting of hydrogen or C_{1-2}alkyl;

R^{N2} is selected from the group consisting of hydrogen or C_{1-2}alkyl;

R^{N3} is selected from the group consisting of hydrogen, C_{1-3}alkyl or C_{1-2}alkylcarbonyl; wherein the C_{1-3}alkyl and C_{1-2}alkylcarbonyl may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or $N(R^aR^b)$;

R^{N4} is selected from the group consisting of hydrogen, C_{1-3}alkyl or C_{1-2}alkylcarbonyl; wherein the C_{1-3}alkyl and C_{1-2}alkylcarbonyl may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or $N(R^aR^b)$;

R^a and R^b are independently selected, for each occurrence, from the group consisting of hydrogen and C_{1-3}alkyl; wherein C_{1-3}alkyl may optionally be substituted by one or more substituents selected from fluorine, cyano, oxo and hydroxyl;

or R^a and R^b, together with the nitrogen to which they are attached, may form a 4-6 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or

N; wherein the 4-6 membered heterocyclic ring may optionally be substituted by one or more substituents selected from the group consisting of fluorine, cyano, oxo or hydroxyl;

R^f is independently selected, for each occurrence, from the group consisting of R^p, hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, (wherein wherein w is 0, 1 or 2), C_{1-6}alkylcarbonyl-$N(R^a)$- and C_{1-6}alkoxycarbonyl-$N(R^a)$-; wherein C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, C_{1-6}alkylcarbonyl-$N(R^a)$-, C_{1-6}alkoxycarbonyl-$N(R^a)$- may be optionally substituted by one or more substituents selected from R^p;

R^g is independently selected for each occurrence from the group consisting of R^p, hydrogen, oxo, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, (wherein w is 0, 1 or 2), C_{1-6}alkylcarbonyl-$N(R^a)$- and C_{1-6}alkoxycarbonyl-$N(R^a)$-; wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, C_{1-6}alkylcarbonyl-$N(R^a)$-, C_{1-6}alkoxycarbonyl-$N(R^a)$- may be optionally substituted by one or more substituents selected from R^p;

R^h is independently selected for each occurrence from the group consisting of hydrogen, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkyl-$S(O)_2$-, C_{1-6}alkoxycarbonyl-, R^iR^jN-carbonyl- and R^iR^jN-SO_2-; wherein C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl and C_{1-6}alkyl-$S(O)_2$-, C_{1-6}alkylcarbonyl- may optionally be substituted by one or more substituents selected from R^p;

R^i and R^j are selected independently for each occurrence from the group consisting of hydrogen, C_{1-4}alkyl C_{3-6}cycloalkyl, heterocyclyl and heterocyclylcarbonyl; wherein C_{1-4}alkyl and C_{3-6}cycloalkyl may be optionally substituted by one or more substituents selected from fluorine, hydroxyl, cyano, R^aR^bN-, R^aR^bN-carbonyl- and C_{1-3}alkoxy and wherein heterocyclyl and heterocyclylcarbonyl may be optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, halo-C_{1-6}-alkyl, hydroxyl-C_{1-6}-alkyl, R^aR^bN-C_{1-6}alkyl- and C_{1-6}-alkoxy-C_{1-6}-alkyl group; and wherein if said heterocyclyl or heterocyclylcarbonyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkyl-$S(O)_2$- and C_{1-6}-alkylcarbonyl;

or R^i and R^j taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-7 membered heterocyclic ring may be optionally substituted on carbon by one

or more substituents selected from the group consisting of fluorine, hydroxyl, oxo, cyano, C_{1-6}alkyl, C_{1-6}alkoxy, R^aR^bN-, R^aR^bN-SO_2- and R^aR^bN-carbonyl-; wherein said C_{1-6}alkyl or C_{1-6}alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and wherein the 4-7 membered heterocyclic ring may be optionally substituted on nitrogen by one or more substituents selected from the group consisting of C_{1-6}alkyl and R^aR^bN-carbonyl-; and wherein said C_{1-6}alkyl may be optionally substituted by fluorine, hydroxyl, cyano;

R^P is independently selected, for each occurrence, from the group consisting of halogen, hydroxyl, cyano, C_{1-6}alkoxy, R^iR^jN-, R^iR^jN-carbonyl-, R^iR^jN-SO_2- and R^iR^jN-carbonyl-$N(R^a)$-;

and pharmaceutically acceptable salts, stereoisomers, esters and prodrugs thereof.

{0007c} In another aspect, there is provided the tricyclic compound represented by:



Formula IV

D^2 is a 5-7 membered partially unsaturated heterocyclic or carbocyclic ring;

X^2 is selected from the group consisting of: $^+$-$C(R^{D1}R^{D2})$-*, $^+$-W^1-*, $^-$-$C(R^{D1}R^{D2})$-$C(R^{D5}R^{D6})$-*, $^+$-W^2-$C(R^{D5}R^{D6})$-*, $^+$-W^2-C(O)-*, $^-$-$C(R^{D1}R^{D2})$-W^4-*, $^-$-$C(R^{D1}R^{D2})$-$C(R^{D3}R^{D4})$-$C(R^{D5}R^{D6})$-*, $^-$-W^2-$C(R^{D3}R^{D4})$-$C(R^{D5}R^{D6})$-*, $^+$-W^2-C(O)-$C(R^{D5}R^{D6})$-*, $^-$-$C(R^{D1}R^{D2})$-W^3-$C(R^{D5}R^{D6})$-*, $^+$-$C(R^{D1}R^{D2})$-W^3-C(O)-*, $^-$-$C(R^{D1}R^{D2})$-$C(R^{D3}R^{D4})$-W^4-* and $^-$-$C(R^{D1}R^{D2})$-C(O)-W^4-*; wherein the $^+$ and * indicate the attachment points of X^2 as indicated in Formula IV;

W^1 is selected from the group consisting of O, S or $N(R^{N1})$;

W^2 is selected from the group consisting of O or $N(R^{N2})$;

W^3 is selected from the group consisting of O or $N(R^{N3})$;

W^4 is selected from the group consisting of O or $N(R^{N4})$;

R^{B1} is selected from the group consisting of H, F, OH, CN, C_{1-2}alkoxy or C_{1-3}alkyl; wherein C_{1-3}alkyl and C_{1-2}alkoxy are optionally substituted by a group selected from OH, C_{1-2}alkoxy, CN or one or more fluorine atoms;

R^{A1} is selected, independently for each occurrence, from the group consisting of hydrogen, hydroxyl, cyano, halogen, C_{1-4}alkyl or C_{1-3}alkoxy; wherein C_{1-4}alkyl, or C_{1-3}alkoxy may be optionally substituted by one or more fluorines;

n is 0, 1, or 2;

R^{A2} is selected from the group consisting of hydrogen, R^iR^jN-, heterocyclyl, heterocyclyloxy and heterocyclyl-(NR^a)-; wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R^g and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R^h; or

R^{A2} is selected from the group consisting of: C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{3-6}alkenyloxy, C_{3-6}alkynyloxy, C_{3-6}cycloalkoxy, C_{1-6}alkyl-$S(O)_w$- (wherein w is 0, 1 or 2), C_{1-6}alkyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-carbonyl-, C_{1-6}alkylcarbonyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-carbonyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-SO_2-, C_{1-6}alkyl-SO_2-$N(R^a)$-, C_{1-6}alkoxycarbonyl-$N(R^a)$-, C_{1-6}alkylcarbonyl-$N(R^a)$-C_{1-6}alkyl-, C_{1-6}alkyl-$N(R^a)$-carbonyl-C_{1-6}alkyl-, C_{1-6}alkoxyC_{1-6}alkyl-; wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{3-6}alkenyloxy, C_{3-6}alkynyloxy, C_{3-6}cycloalkoxy, C_{1-6}alkyl-$S(O)_w$-, C_{1-6}alkyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-carbonyl-, C_{1-6}alkylcarbonyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-carbonyl-$N(R^a)$-, C_{1-6}alkyl-$N(R^a)$-SO_2-, C_{1-6}alkyl-SO_2-$N(R^a)$-, C_{1-6}alkoxycarbonyl-$N(R^a)$-, C_{1-6}alkylcarbonyl-$N(R^a)C_{1-6}$alkyl-, C_{1-6}alkyl-$N(R^a)$-carbonyl-C_{1-6}alkyl-, C_{1-6}alkoxy-C_{1-6}alkyl may optionally be substituted by R^p, phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR^a)-, heterocyclyl, heterocyclyloxy or heterocyclyl-$N(R^a)$-; and wherein said heteroaryl or phenyl may optionally be substituted with one or more substituents selected from R^f; and wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R^g; and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R^h;

R^{D1} and R^{D2} are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl and C_{1-2}alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano or hydroxyl;

R^{D3} and R^{D4} are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C_{1-3}alkyl or C_{1-3}alkoxy; wherein the C_{1-3} alkyl and C_{1-3} alkoxy may

optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or $N(R^aR^b)$;

R^{D5} and R^{D6} are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl and C_{1-2}alkoxy may optionally be substituted by a substituent or substituents selected from the group consisting of: one or more fluorine atoms,cyano, hydroxyl or $N(R^aR^b)$;

R^{C1} is selected from the group consisting of hydrogen, halogen, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl or C_{1-2}alkoxy may optionally be substituted by one or more fluorine atoms;

R^{C2} is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C_{1-2}alkyl or C_{1-2}alkoxy; wherein the C_{1-2}alkyl and C_{1-2}alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or $N(R^aR^b)$;

R^{N1} is selected from the group consisting of hydrogen or C_{1-2}alkyl;

R^{N2} is selected from the group consisting of hydrogen or C_{1-2}alkyl;

R^{N3} is selected from the group consisting of hydrogen, C_{1-3}alkyl or C_{1-2}alkylcarbonyl; wherein the C_{1-3}alkyl and C_{1-2}alkylcarbonyl may optionally be substituted by a substituent or substituents selected from the group consisting of: one or more fluorines, cyano, hydroxyl or $N(R^aR^b)$;

R^{N4} is selected from the group consisting of hydrogen, C_{1-3}alkyl or C_{1-2}alkylcarbonyl; wherein the C_{1-3}alkyl and C_{1-2}alkylcarbonyl may optionally be substituted by a substituent or substituents selected from the group consisting of: one or more fluorines, cyano, hydroxyl or $N(R^aR^b)$;

R^a and R^b are independently selected, for each occurrence, from the group consisting of hydrogen and C_{1-3}alkyl; wherein C_{1-3}alkyl may optionally be substituted by one or more substituents selected from fluorine, cyano, oxo and hydroxyl;

or R^a and R^b, together with the nitrogen to which they are attached, may form a 4-6 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring may optionally be substituted by one or more substituents selected from the group consisting of fluorine, cyano, oxo or hydroxyl;

R^f is independently selected, for each occurrence, from the group consisting of R^P, hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-,

(wherein wherein w is 0, 1 or 2), C_{1-6}alkylcarbonyl-N(R^a)- and C_{1-6}alkoxycarbonyl-N(R^a)-; wherein C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, C_{1-6}alkylcarbonyl-N(R^a)-, C_{1-6}alkoxycarbonyl-N(R^a)- may be optionally substituted by one or more substituents selected from R^p;

R^g is independently selected for each occurrence from the group consisting of R^p, hydrogen, oxo, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, (wherein w is 0, 1 or 2), C_{1-6}alkylcarbonyl-N(R^a)- and C_{1-6}alkoxycarbonyl-N(R^a)-; wherein C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-6}alkyl-$S(O)_w$-, C_{1-6}alkylcarbonyl-N(R^a)-, C_{1-6}alkoxycarbonyl-N(R^a)- may be optionally substituted by one or more substituents selected from R^p;

R^h is independently selected for each occurrence from the group consisting of hydrogen, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkyl-$S(O)_2$-, C_{1-6}alkoxycarbonyl-, R^iR^jN-carbonyl- and R^iR^jN-SO_2-; wherein C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl and C_{1-6}alkyl-$S(O)_2$-, C_{1-6}alkylcarbonyl- may optionally be substituted by one or more substituents selected from R^p;

R^i and R^j are selected independently for each occurrence from the group consisting of hydrogen, C_{1-4}alkyl, C_{3-6}cycloalkyl, heterocyclyl and heterocyclylcarbonyl; wherein C_{1-4}alkyl and C_{3-6}cycloalkyl may be optionally substituted by one or more substituents selected from fluorine, hydroxyl, cyano, R^aR^bN-, R^aR^bN-carbonyl- and C_{1-3}alkoxy and wherein heterocyclyl and heterocyclylcarbonyl may be optionally substituted by one or more substituents selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, halo-C_{1-6}-alkyl, hydroxyl-C_{1-6}-alkyl, R^aR^bN-C_{1-6}alkyl- and C_{1-6}-alkoxy-C_{1-6}-alkyl group; and wherein if said heterocyclyl or heterocyclylcarbonyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-6}cycloalkyl, C_{1-6}alkyl-$S(O)_2$- and C_{1-6}-alkylcarbonyl;or R^i and R^j taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-7 membered heterocyclic ring may be optionally substituted on carbon by one or more substituents selected from the group consisting of fluorine, hydroxyl, oxo, cyano, C_{1-6}alkyl, C_{1-6}alkoxy, R^aR^bN-, R^aR^bN-SO_2- and R^aR^bN-carbonyl-; wherein said C_{1-6}alkyl or C_{1-6}alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and wherein the 4-7 membered heterocyclic ring may be optionally substituted on nitrogen by one or more substituents selected from the group consisting of C_{1-6}alkyl and R^aR^bN-carbonyl-; and wherein

said C_{1-6}alkyl may be optionally substituted by one or more substituents selected from the group consisting of fluorine, hydroxyl, cyano;

R^p is independently selected, for each occurrence, from the group consisting of halogen, hydroxyl, cyano, C_{1-6}alkoxy, R^iR^jN-, R^iR^jN-carbonyl-, R^iR^jN-SO_2- and R^iR^jN-carbonyl-$N(R^a)$-;

and pharmaceutically acceptable salts, stereoisomers, esters and prodrugs thereof.

[0007d] In another aspect, there is provided a compound selected from the group consisting of: cis-(3aRS,9bRS)-7-(benzenesulfonylamino)-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid; cis-(3aRS,9bRS)-7-[2-(3-diethylaminopropyl)-4-fluorobenzenesulfonyl-amino]-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid; cis-(3aRS,9bRS)-7-[2-(3-{pyrrolidin-1-yl}propyl)-4-fluorobenzene-sulfonylamino]-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid; cis-(3aRS,9bRS)-7-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluoro-benzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid; cis-(3aR,9bR)-7-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid; cis-(3aS,9bS)-7-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid; 7-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonyl-amino]-1,2-dihydrofuro[2,3-c]quinoline-6-carboxylic acid formate salt; 7-(benzenesulfonylamino))-1,2-dihydrofuro[2,3-c]quinoline-6-carboxylic acid formate salt; cis-(3aRS,9bRS)-7-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,2,3a,4,5,9b-hexahydrofuro[2,3-c]quinoline-6-carboxylic acid; (1aRS,7bSR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aR,7bS)- 5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-7b-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-((E)-3-diethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-7b-methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; cis-(3aRS,9bRS)-7-[2-(4-dimethylamino-butylamino)-benzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid; (1aR,7bS)-5-[2-(3-diethylaminopropyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzene-sulfonylamino]-1,1-difluoro-1,1a,2,7b-

tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzene-sulfonylamino]-1,1-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)-4-fluorobenzene-sulfonylamino]-1,1-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2((Z)-3-ethylaminoprop-1-enyl)-4-fluoro-benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2((Z)-3-ethylaminoprop-1-enyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2((Z)-3-ethylaminoprop-1-enyl)-4-fluorobenzene-sulfonylamino]-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2[(Z)-3-(pyrrolidin-1-yl)prop-1-enyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aR,7bS)-5-{2[(Z)-3-(pyrrolidin-1-yl)prop-1-enyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-{2[(Z)-3-(pyrrolidin-1-yl)prop-1-enyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(3-dimethylamino-propylamino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2-(3-dimethylaminopropylamino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2-(3-dimethylamino-propylamino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(4-dimethylaminobutylamino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2-(4-dimethylaminobutyl-amino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2-(4-dimethylaminobutylamino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(5-dimethylamino-pentylamino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2[(Z)-3-(propan-2-yl)aminoprop-1-enyl]-4-fluorobenzene-sulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2[(Z)-3-((S)-3-hydroxypyrrolidin-1-yl)aminoprop-1-enyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2[(Z)-3-((R)-3-hydroxypyrrolidin-1-yl)aminoprop-1-enyl]-4-fluorobenzene-sulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2((Z)-4-diethylaminobut-1-enyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2((Z)-4-diethylaminobut-1-

enyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2((Z)-4-diethylaminobut-1-enyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-(4-ethylpiperazin-1-yl)-ethyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2[(Z)-3-(azetidin-1-yl)prop-1-enyl]-4-fluorobenzene-sulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2[(Z)-3-(3-hydroxyazetidin-1-yl)prop-1-enyl]-4-fluorobenzene-sulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2[(Z)-3-(azetidin-1-yl)propyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2((Z)-4-diethylaminobutyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[N-(4-dimethylamino-butyl)-N-methylamino]-benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidin-3-ylcarbamoyl)methyl]-4-fluoro-benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(1-ethylazetidin-3-yl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((R)-1-ethylpyrrolidin-3-ylcarbamoyl)methyl]-4-fluorobenzenesulfonyl-amino}-1,1a,2,7b-tetrahydro-cyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-(pyrrolidin-1-yl)-ethyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-((R)-1-ethylpyrrolidin-3-ylmethyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2-((R)-1-ethylpyrrolidin-3-ylmethyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2-((R)-1-ethylpyrrolidin-3-ylmethyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidin-2-yl)cabonyl-aminomethyl]-4-fluorobenzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(4-dimethylaminobutyrylamino)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-((S)-1-ethyl-pyrrolidin-3-ylmethyl)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(3-dimethylaminopropylcarbamoyl)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-(2-{[N-((S)-1-ethyl-pyrrolidin-3-yl)-N-methylcarbamoyl]methyl}-4-fluoro-benzenesulfonylamino)-1,1a,2,7b-

tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-(2-{[N-((R)-1-ethylpyrrolidin-3-yl)-N-methylcarbamoyl]methyl}-4-fluoro-benzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-((S)-1-ethylpyrrolidin-2-yl)ethylamino]-benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-((R)-1-ethylpyrrolidin-2-yl)ethylamino]-benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(3-N,N,-diethylaminopropylamino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-(2-{[((R)-1-ethylpyrrolidine-2-yl)carbonyl-amino]methyl}-4-fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[(1-ethylazetidin-3-ylmethyl)amino]benzene-sulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2-((Z)-3-diethylaminoprop-1-enyl)benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aS,7bR)-5-[2-((Z)-3-diethylaminoprop-1-enyl)benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-(2-{N-[((R)-1-ethylpyrrolidine-2-yl)carbonyl]-N-methylaminomethyl}-4-fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-(2-{N-[((S)-1-ethylpyrrolidine-2-yl)carbonyl]-N-methylamino-methyl}-4-fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(4-dimethylaminobutylamino)-4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((R)-1-ethylpyrrolidin-3-ylmethyl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidin-3-ylmethyl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(4-ethyl-2-oxopiperazin-1-ylmethyl)-4-fluorobenzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-(1-ethylpiperidin-4-ylmethyl)-4-fluoro-benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-(1-ethylazetidin-3-yl)ethyl]-4-fluorobenzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((S)-1-azabicyclo[2.2.2]oct-3-yl)amino]benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((R)-1-azabicyclo[2.2.2]oct-3-yl)amino]benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-(2-{[((S)-1-ethylpyrrolidine-3-carbonyl)-amino]methyl}-4-fluoro-benzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-((R)-1-

ethylpyrrolidin-3-ylamino)ethyl]-4-fluoro-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((R)-1-ethylpyrrolidin-3-yl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidin-3-yl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-(2-{[((R)-1-ethylpyrrolidine-3-carbonyl)amino]-methyl}-4-fluoro-benzenesulfonylamino)-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-[2-((Z)-3-diethylamino-2-methylprop-1-enyl)-4-fluorobenzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-((R)-1-ethylpyrrolidin-3-yl)ethylamino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aRS,7bSR)-5-{2-[2-((S)-1-ethylpyrrolidin-3-yl)ethylamino]-benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2-((S)-1-ethylpyrrolidin-3-yloxymethyl)-4-fluoro-benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aR,7bS)-5-[2-((R)-1-ethylpyrrolidin-3-yloxymethyl)-4-fluoro-benzenesulfonylamino]-1,1a,2,7b-tetrahydro-cyclopropa-[c]chromene-4-carboxylic acid; (1aR,7bS) -5-[2-(1-ethylpiperidin-3-ylmethyl)-4-fluorobenzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aR,7bS)-5-{2-[2-((R)-1-ethylpyrrolidin-2-yl)ethyl]-4-fluorobenzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; and pharmaceutically acceptable salts, stereoisomers, esters and prodrugs thereof.

[0007e] In another aspect, there is provided a pharmaceutically acceptable composition comprising a compound as defined above and a pharmaceutically acceptable excipient.

[0007f] In another aspect, there is provided the use of a compound as defined above in the manufacture of a medicament for treating and/or controlling obesity in a patient in need thereof.

[0007g] In another aspect, there is provided the use of a compound as defined above in the manufacture of a medicament for inducing weight loss in a patient in need thereof.